Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ATG 101

Next Previous
Drug Profile

ATG 101

Alternative Names: ATG-101; ATN-101; Ori-Bs-001; PD-L1/4-1BB bi-specific antibody; YN-051

Latest Information Update: 20 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OriCell Therapeutics
  • Developer Antengene Corporation
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; Programmed cell death-1 ligand-1 inhibitors; Regulatory T-lymphocyte inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 09 Jun 2025 Antengene Biologics Limited terminates a phase-I trial in Non-Hodgkin's lymphoma and Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA and Australia (IV) due to the recent changes in the competitor landscape and strategic consideration (NCT04986865)
  • 28 Apr 2025 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(In the elderly, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater, In adults) in China (IV)
  • 28 Apr 2025 No recent reports of development identified for phase-I development in Solid-tumours(In the elderly, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater, In adults) in China (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top